A genetic test promises something quietly powerful: a look at your own biology, read from a little saliva, with answers about the years ahead. It is an appealing idea, and for many Indian families it is also a confusing one. Are these tests accurate? Can you trust what the report says? And if you can, what exactly are you trusting it to tell you?
These are fair questions, and they deserve a straight answer rather than a sales pitch. The honest version is this: a good DNA health test is highly accurate at reading your genes, and far more modest at predicting your future. Those are two different things, and most of the confusion around genetic testing comes from treating them as one.
Two kinds of accuracy, often confused
When people ask whether a DNA test is accurate, they usually mean one of two things without realising they are separate questions.
The first is analytical accuracy: did the laboratory read your DNA correctly? Here, the technology is genuinely strong. Modern sequencing and genotyping, run in an accredited laboratory, can read the specific letters of your genetic code with very high reliability. If a report says you carry a particular variant, a well-run lab is almost certainly right about that fact. This is the part that has improved enormously, and the part where Indian laboratories accredited to international standards now perform on par with the best.
The second is interpretive accuracy: what does that variant actually mean for your health? This is where honesty is required. Knowing you carry a variant is a fact. Knowing what it does to your risk of heart disease or diabetes is an interpretation, and interpretation is probabilistic, evolving, and far less certain than the headline numbers suggest.
A test can be near-perfect on the first count and still leave real uncertainty on the second. Both can be true at the same time, and a responsible report says so.
What a genetic test can tell you
Used well, a genetic health test offers several things of real value.
It can identify whether you carry specific, well-established variants, for instance those associated with how your body processes certain nutrients, medicines, or fats. For a smaller number of single-gene conditions, the link between a variant and its effect is strong and clinically meaningful, which is why genetic testing has a settled place in areas such as carrier screening and pharmacogenomics.
For common, complex conditions such as type 2 diabetes, heart disease and many cancers, a test can estimate a predisposition. It reads many small genetic signals and combines them into a sense of whether your inherited risk sits above or below average. This can be genuinely useful as an early prompt to pay attention, particularly when it agrees with your family history.
What makes this matter in India is scale. The ICMR-INDIAB national study estimated that, in 2021, around 101 million Indians were living with diabetes and another 136 million with prediabetes (Lancet Diabetes and Endocrinology, 2023). Much of that risk builds silently, years before a diagnosis. A genetic predisposition, read early, is one more signal that may help a family act sooner rather than later. That is the quiet case for these tests, not prophecy, but a head start. We have written more about this shift in thinking in Don't Wait for the Diagnosis.
What a genetic test cannot tell you
Here is the part most marketing leaves out.
A predisposition is not a diagnosis, and it is not destiny. A test that reports higher inherited risk for a condition is saying the odds may be raised, not that you have the condition, and not that you will develop it. For most common diseases, genetics is only one contributor among many. Diet, sleep, activity, environment and chance all shape the outcome, and a great deal of that is modifiable. A higher-risk result is best read as a reason to engage, not a sentence to fear.
Equally, a reassuring result is not a clean bill of health. A test that finds no notable variants for a given condition has not ruled it out. Someone can carry an average genetic risk and still develop a disease through lifestyle or factors no test captures. Genetic information narrows the picture; it does not complete it.
And the science is still moving. The list of variants we understand grows every year, which means a report is a snapshot of current knowledge, not a final verdict. A variant considered unremarkable today may be better understood tomorrow. This is a strength of the field, not a flaw, but it is a reason to treat any single report as a living document rather than a closing statement.
This is why we are careful, in every WinDNA report, to use the language of probability and association rather than certainty. It is not caution for its own sake. It is simply the most accurate way to describe what the science can honestly support.
Why South Asian data matters more than most realise
There is a quieter accuracy problem that affects Indian families in particular, and it has nothing to do with laboratory quality.
Most of what we know about how genetic variants relate to disease comes from large studies, and for years those studies were run overwhelmingly in people of European ancestry. One analysis found that 67 percent of polygenic scoring studies between 2008 and 2017 included exclusively European-ancestry participants, with South Asian and other populations sharply under-represented (Nature Communications, Duncan et al., 2019).
This matters because the way risk is calculated does not always transfer cleanly across populations. The same study found that risk scores built mainly on European data tend to perform less well when applied to other ancestries. A genetic test can read an Indian person's DNA perfectly and still interpret it through a lens calibrated on a different population, which can make the risk estimate less reliable for the very families relying on it.
The answer is not to distrust genetic testing, but to ask where its interpretation comes from. Reports calibrated against South Asian reference data, and read by clinicians who understand Indian biology, diet and disease patterns, are on firmer ground than those that quietly assume one population fits all. When you read about how prevention should be built around your own biology in The Power of Personalised Genetic Testing in Preventive Health, this is the foundation it rests on.
Why the human in the loop still matters
It is tempting to imagine genetic testing as a fully automated affair: spit, post, receive your future by email. The reality, done responsibly, looks different.
A raw genetic file is not a health plan. Someone has to interpret it in the context of your family history, your current health, your medicines and your life, and to know which findings deserve attention and which are noise. That judgement is clinical, not algorithmic. Software can sort variants; it cannot yet weigh them against the whole person sitting in front of it. We have written about where technology genuinely helps, and where it does not, in AI and the Future of Healthcare.
This is also the honest answer to whether genetic testing is worth it. A test handed over without interpretation is a document. A test read with you, by someone qualified to explain what it does and does not mean, is something closer to useful. The value sits in the conversation as much as in the sequence.
So, are they accurate?
Yes, in the way that matters most: a good test, run in an accredited laboratory, reads your DNA reliably. And no, in the way many people hope: it cannot tell you what your future holds with certainty, because that certainty does not exist.
What a genetic health test offers an Indian family is not a verdict but a vantage point, an earlier and more personal view of where your biology may be steering you, so that you can make choices while choices still count. Read that way, with honest expectations and a clinician alongside, it earns its place in preventive health. If you would like to understand how WinDNA reads and reviews these results, The Science page sets out our approach in plain terms.
References
- ICMR-INDIAB national cross-sectional study, The Lancet Diabetes and Endocrinology, 2023. View source
- Duncan, L., et al., Analysis of polygenic risk score usage and performance in diverse human populations, Nature Communications, 2019. View source